Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
Therapeutic Advances in Gastroenterology · 2025-07 · 18
DOI: 10.1177/17562848251342864 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 09.06.2025. Verfasst von Ding Peng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xuanwu Hospital Capital Medical University, Changchun Street 45#, 100053 Beijing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Gastrointestinal bleeding (GIB) is a critical clinical emergency associated with high morbidity and mortality. The widespread use of antithrombotic agents, including antiplatelet and anticoagulant medications, has increased the incidence of GIB.
Objectives
Our study aims to address this gap by evaluating the impact of antithrombotic therapy on both 28-day mortality and rebleeding risk.
Design
Retrospective cohort study using propensity score-based methods to address confounding.
Methods
Data were extracted from three independent databases (MIMIC-IV, NWICU, and Xuanwu Hospital) spanning 2008–2022. inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics. Weighted logistic regression models assessed outcomes across antiplatelet, anticoagulant, and combination therapy subgroups.
Results
After inverse probability of treatment weighting (IPTW) adjustment, the antithrombotic group maintained a significantly elevated rebleeding rate (19.9% vs 10.5%, p < 0.001) and an increased risk of rebleeding (odds ratio (OR) = 2.118, 95% confidence interval (CI): 1.577–2.845, p < 0.001). Conversely, the 28-day mortality was significantly lower in the antithrombotic group postadjustment (8.2% vs 12.5%, p = 0.022; OR = 0.621, 95% CI: 0.412–0.935, p = 0.023). Notably, early resumption of antithrombotic therapy (within 3 days) significantly increased the risk of mortality.
Conclusion
Our study suggests that while antithrombotic therapy reduces 28-day mortality, it significantly increases rebleeding risk. Notably, the use of anticoagulants or combination therapy is linked to the highest rebleeding risk, compared to antiplatelets. Additionally, resuming antithrombotic therapy too early (i.e., within 3 days) may further elevate the risk of mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Xuanwu Hospital Capital Medical University, Changchun Street 45#, 100053 Beijing, China.
ORCID-Profile: Ding Peng, Huihong Zhai
Zitieren
APA
Peng, D., & Zhai, H. (2025). Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study. Therapeutic Advances in Gastroenterology, 18. https://doi.org/10.1177/17562848251342864
Vancouver
Peng D, Zhai H. Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study. Therapeutic Advances in Gastroenterology. 2025;18. doi:10.1177/17562848251342864
BibTeX
@article{Peng2025,
author = {Peng, Ding and Zhai, Huihong},
title = {Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study},
journal = {Therapeutic Advances in Gastroenterology},
year = {2025},
volume = {18},
doi = {10.1177/17562848251342864}
}
EUVIMED